查詢結果分析
相關文獻
- The Therapeutic Effects of Terazosin Alone or in Combination with Finasteride on Patients with Benign Prostatic Hyperplasia
- 臺灣男性雄性基因禿治療現況與最新發展
- Free-to-total Serum Prostate Specific Antigen Ratio in Chinese Men
- Changes of Serum Prostate-Specific Antigen Before and After Transurethral Vaporization of Prostate for Benign Prostatic Hyperplasia
- Early Experience with High Intensity Focused Ultrasound for the Treatment of Benign Prostate Hyperplasia
- 護理一位攝護腺肥大病患的經驗
- Effect of High-Dose Ketoconazole Treatment on Serum Levels of Testosterone and Cortisol in Male Dogs
- 運動影響睪固酮激素變化之因素
- 土番鴨生長期間血漿之雌素二醇﹣17β與睪固酮濃度變化
- 良性攝護腺肥大病患之尿流動力學檢查
頁籤選單縮合
題 名 | The Therapeutic Effects of Terazosin Alone or in Combination with Finasteride on Patients with Benign Prostatic Hyperplasia=單獨使用Terazosin或合併使用Terazosin和Finasteride對治療良性攝護腺肥大病人之效果 |
---|---|
作 者 | 黃一勝; 仇光宇; | 書刊名 | 中華民國泌尿科醫學會雜誌 |
卷 期 | 9:1 1998.03[民87.03] |
頁 次 | 頁12-17 |
分類號 | 416.275 |
關鍵詞 | 良性攝護腺肥大; 睪固酮; 二氫睪固酮; Benigh prostatic hyperplasia; Finasteride; Terazosin; |
語 文 | 英文(English) |
中文摘要 | 目前用來治療良性攝護腺肥大的藥物有兩種,包括�恁@接受體抑制物(如terazosin) 和5�恁@還原抑制物(如finasteride)。理論上,合併使用這兩種藥物,應有相加或相乘的效果。 本研究總共徵得78位良性攝護線肥大的病人參與。每個病人先服用一個月的terazosin(2毫 克/天)後,再合併服用finasteride5(毫克/天)12個月。過程中,我們評估其症狀係數,最高尿 流速及攝護線體積等各種參數之變化。最高尿流速在單獨服用terazosin期(12.2±4.6毫升/秒 比13.8±3.3毫升/秒,p<0.05)及合併使用期(增加11.4-14.8%, p<0.05)都呈有意義之變化, 但此兩治療期作比較時,則發現並未呈有意義的差別。症狀指數在terazosin期及合併使用 期,也都呈有意義的降低下來,但與最高尿流速一樣,treazosin期和合併使用期之間並無有 意義之差別。至於攝護腺之體積變化,在terazosin期並沒有意義的差別,但在合併使用期 之前6個月,呈有意義之差別(26.2±6.3毫升比23.4±5.8毫升;26.2±6.3毫升比22.0±4.7 毫升,p<0.01),不過接下來的6個月,攝護腺又慢慢回復原來的體積。PSA值在terazosin 期並無有意義變化,但在合併使用用期全程都呈現有意義的減低(27.1-38.0%, p<0.01)。藥物 的副作用方面暈眩(9.0%),鼻塞(5.1%)及陽萎(2%)是terazosin治療期較常用的症狀,而陽萎 (16.3%),性慾減退(4.1%)及逆行性射精(6.1%)則是合併使用期的普遍副作用。本研究顯示, terazosin單獨使用呈現有效的治療結果,合併使用terazosin和finasteride 來治療良性攝護腺 肥大病人,除了前6個月其攝護腺體積呈有意義的縮小外,在客觀方面(最高尿流速)及主觀 方面(症狀指數)並沒有顯示比單獨使用terazosin有效。 |
英文摘要 | Contemporary medical treatment of benigh prostatic hyperplasia (BPH) includes aderenoreceptor blocker (such as terazosin)and 5 a-reductase inhibitor (finasteride). Additive or synergistic effect may be demonstrated if these two drugs are administered in combination. Seventy- eight patients with BPH were enrolled in this study to evaluate the effects of these 2 medications. Each patient received terazosin (2 mg./day) for one month, then received combined therapy of terazosin (2 mg/day)and finasteride (5 mg./day) for 12 months. Peak urinary flow rate, symptom score and prostatic volume were determined at base line and during each period for comparison. Peak flow rate increased significantly from base line to terazosin alone period (12.2±4.6 ml/sec. Vs 13.8±3.3 ml/sec. P<0.05), as well as combined period (11.4-14.8%), but no significant difference shown between terazosin alone and combined therapy. Symptom score decreased significantly during terazosin alone and combined periods. Similarly, no significant difference was found between terazosin alone and combined periods. Prostate volume revealed no significant reduction during the terazosin alone period, but reduced significantly at month 4 and month 7 of combined therapy (26.2±6.3 cm vs 23.4±5.8 cm , 26.2 ±6.3 cm vs 22.0±4.7 cm , p<0.01), and then returned gradually. PSA showed no change in terazosin period but decreased significantly throughout the combined period (from 27.1% to 38.0%, p<0.01). Adverse side effects such as dizziness (9.0%), nasal obstraction (5.1%) and impotence (2.0%) were found primarily during terazosin alone treatment, while impotence (16.3%), loss of libido (4.1%) and retrograde ejaculation (6.1%) were noted mostly during combined therapy. In conclusion, terazosin alone was effective for treatment with BPH. Combined therapy of terazosin and finasteride, though may reduce prostatic volume significantly, showed no additive effect compared with terazosin alone, evaluated either objectively (peak flow rate) or subjectively (symptom score). |
本系統中英文摘要資訊取自各篇刊載內容。